Navigation Links
Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
Date:4/22/2009

, such live vaccines are used for other diseases including smallpox, polio, and measles. When the attenuated parasite is given to individuals, they are expected to become immune to malaria and not get sick.

Evidence that the Sanaria approach has the potential to confer high levels of protection against malaria comes from previous studies in which volunteers were exposed to the bites of mosquitoes harboring weakened parasites. While the technological challenges associated with translating this approach into an effective and safe vaccine based on live parasites had been widely viewed as insurmountable, Sanaria has developed novel technologies and constructed a unique manufacturing facility that allows scientists to manufacture the candidate vaccine.

"The Sanaria team has been able to systematically overcome obstacle after obstacle in a remarkably short time. I look forward to working with the rest of the team to bring this vaccine over the finish line and into widespread use to prevent the devastating illnesses and deaths caused by malaria," said Adel Mahmoud, former president of Merck Vaccines and member of Sanaria's board of directors.

Ultimately, the measure of success will be a safe, effective licensed vaccine that is widely deployed to prevent malaria, especially in African children.

"The first clinical trial of Sanaria's candidate malaria vaccine is a watershed event. It is the culmination of a remarkable translational research effort by Sanaria directed at realizing the dream of a practical malaria vaccine preparation based upon whole parasites," states Michael Good, Director of the Queensland Institute of Medical Research.

Myron M. Levine, Director of the University of Maryland School of Medicine's Center for Vaccine Development notes, "Development of Sanaria's vaccine candidate is based in part on the findings from parallel studies conducted in the early 1970s by t
'/>"/>

SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
2. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
5. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
6. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
7. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
8. Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye
9. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
10. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
11. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 BRIC Gynecological Devices Market Outlook ... GlobalData,s new report, "BRIC Gynecological Devices Market Outlook ... BRIC Gynecological Devices market. The report provides value, ... and average prices (in US dollars) within market ... (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and ...
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... Pomerantz LLP is investigating claims on behalf ... the "Company") (NASDAQ: PDLI).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... and/or directors have violated Sections 10(b) and 20(a) of ... On September 17, 2014, the Company announced that On ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
... 2012 Synteract , Inc., a full-service contract ... developing new therapies to combat the growing issue of ... Great Strides fundraising walk to benefit the Cystic ... Rempex (on behalf of Aptalis Pharma) are also working ...
... Ind., May 2, 2012  Hill-Rom Holdings, Inc. (NYSE: ... declared a fiscal year 2012 third quarter dividend of $0.125 ... to shareholders of record as of the close of business ... HOLDINGS, INC. Hill-Rom is a leading worldwide manufacturer ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2
(Date:9/17/2014)... 17, 2014 Final Cut Pro X plugin ... 5k from Pixel Film Studios. , “ProBlue 5k is a ... from good to epic,” said Christina Austin, CEO of Pixel ... 5k is a definite game changer.” , ProBlue 5k is ... any filmmaker ! This footage compilation of over 100 ...
(Date:9/17/2014)... September 17, 2014 People who struggle to ... head to http://www.perwickstrom.com and get the answer by ... to point out, is that a business plan and a ... work together, commented Per Wickstrom. “The way I view it ... a business strategy which is part two.” , According ...
(Date:9/17/2014)... Chicago IL (PRWEB) September 17, 2014 ... of Pseudomonas aeruginosa infections allegedly caused by Non-Sterile ... to learn more about their options for legal recourse. ... & Drug Administration (FDA) in March 2012, after the ... Pseudomonas aeruginosa at William Beaumont Hospital in Royal Oak, ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. ... to household chemicals known as phthalates might increase a ... reported in a new study. Children had nearly ... age 5 and 11 if their mothers were exposed ... thal-ates), the researchers found. The two phthalates were butylbenzyl ...
(Date:9/17/2014)... Texas (PRWEB) September 17, 2014 Prevention ... outbreak that is hospitalizing scores of infants, children and ... says Dr. Kirk Mahon, medical director of Legacy ER ... “There have been no reported cases of EV-D68 so ... and Louisiana, that could change,” he said. “Implementing prevention ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... ... ... , , ... ...
... , ... plans to address neighborhood concerns. , ... South Boston, MA (PRWEB) March 1, 2010 -- Fenway Bark today announced operational changes ... before the City of Boston Zoning Board of Appeal, to request an Interim Planning Overlay ...
... ... ... ... ...
... , ... ... ... ...
... ... , ... , , , ... MCKINNEY, ...
... ... , ... , , , , ... ...
Cached Medicine News:Health News:Northstar Management Forecasts a Loss of $1.2 Million for 2010 at Its Palladium for Surgery -- Houston, Ltd. Centre 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 2Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 4Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 5Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7Health News:Torchmark Corporation Declares Dividend and Resumes Stock Repurchases 2Health News:MedCath Corporation Announces Decision to Consider Strategic Options 2
Foley Catheters (Latex) 3-Way...
ULTRAMER Foley Catheter...
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone-Coated Foley Catheter 2-Way...
Medicine Products: